Total
0
Shares
Cann Group (ASX:CAN) - CEO, Peter Crock
CEO, Peter Crock
Source: La Trobe University
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cann Group (CAN) and Emyria (EMD) are collaborating to accelerate the registration of a low-dose, CBD-only capsule with Australia’s Therapeutic Goods Administration (TGA)
  • Under the agreement, Emyria’s EMD-003 drug development program will use Cann’s Gelpell technology for treating as-yet un-met needs in mental health
  • A successful registration as a schedule three medicine would result in an over the counter, pharmacist-only CBD medicine
  • A joint project committee will be formed to oversee the allocation of registration costs and the development of commercialisation agreements
  • Emyria’s drug development and clinical team will lead the registration program
  • Cann Group is down 3.51 per cent, trading at 55 cents, while Emyria is up 5.71 per cent at 18.5 cent per share


Cann Group (CAN) and Emyria (EMD) are collaborating to accelerate the registration of a low-dose, CBD-only capsule with Australia’s Therapeutic Goods Administration (TGA).

A successful registration as a schedule three medicine would result in an over the counter, pharmacist-only CBD medicine.

Under the agreement, Emyria’s EMD-003 drug development program will use Cann Group’s proprietary Gelpell microsphere technology as the basis for seeking a schedule three registration for treating un-met needs in mental health.

Cann Group’s Gelpell microsphere formulation embeds CBD in small gelatine beads that are packed in hard gastro-resistant capsules. Emyria’s EMD-003 then targets psychological distress and the symptoms of anxiety, depression and stress.

“This partnership greatly accelerates Emyria’s EMD-003 drug development program by combining Emyria’s unique clinical data and drug development expertise with Cann Group’s best-in-class CBD delivery technology,” said Emyria’s Managing Director, Dr Michael Winlo.

A joint project committee will be formed to oversee the allocation of registration costs and the development of commercialisation agreements.

Cann Group recently acquired the rights to Gelpell technology after purchasing the Satipharm group of companies, which commercialised a CBD product using the technology.

Cann Group plans to incorporate manufacturing of the microsphere formulation in its new production facility, currently under construction near Mildura.

The collaboration between companies capitalises on a number of milestones that have already been met, including phase one trials completed for 10 milligram and 100 milligram doses of the Satipharm capsule.

Satipharm CBD has been shown to have 3.5 times greater bioavailability compared to oil preparations at 100 grams and real-world data on more than 170 patients taking the Satipharm CBD capsule.

“Satipharm CBD has already completed robust stability testing as well as Phase 1 clinical trials as required by the TGA. This allows us to move straight to pivotal clinical outcomes trials saving significant time and money,” said Dr Michael Winlo.

“At Emyria, we already have deep insights into how the Satipharm product performs clinically, having written over 400 Satipharm prescriptions to more than 170 patients. This de-risks the pivotal clinical outcomes trials required as an important first step towards registration with the TGA.”

Emyria’s drug development and clinical team will lead the registration program.

Pivotal clinical trials are in advanced stages of planning and are being guided by insights from Emyria Data for more than 3500 patients treated at Emyria’s Emerald Clinics.

Cann Group is down 3.51 per cent, trading at 55 cents, while Emyria is up 5.71 per cent at 18.5 cent per share at 1:00 pm AEDT.

CAN by the numbers
More From The Market Herald
Danodan Hempworks LLC - Founder, Daniel Stoops

" FijiKava (ASX:FIJ) acquires Danodan Hempworks and US patent

Medicinal kava company FijiKava (ASX:FIJ) completes the acquisition of Danodan Hempworks, including its CBD extraction US…
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon

" Little Green Pharma (ASX:LGP) buds cannabis oil distribution agreement in Germany

Little Green Pharma (ASX:LGP) enters a three-year distribution agreement to market its LGP cannabis oils in…

" Recce Pharmaceuticals (ASX:RCE) receives positive safety data from second cohort of Phase I Clinical Trial

Recce Pharmaceuticals (ASX:RCE) has released positive safety data from its second cohort of subjects for its…
Virtus Health (ASX:VRT) - CEO & Managing Director, Kate Munnings

" Virtus Health (ASX:VRT) has non-urgent elective surgeries suspended in NSW & VIC

Virtus Health (ASX:VRT) has had its non-urgent elective surgeries suspended in NSW and Victoria as the…